Stock Evaluator: Gyre Therapeutics, Inc. (GYRE)

Gyre Therapeutics, Inc. GYRE

$4.43 0.09 2.07%
November 19, 2026 2:37:42 PM EST November 10, 2021 Volume: 203,463
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573, which is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.

Commentary & Analysis


Financial Summary

Share Statistics GYRE Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $475.0 $213.9 38%
Shares Out (Mil) 106.3 55.4 63%
Institutional Ownership 62.1% 93.3% 39%
Float (Mil) 39.4 40.6 41%
Beta 4.92 0.98 99%
Avg Daily Volume (000s) 273 597 49%
Price Change
(52-week)
(45.9%) 40.9% 22%
Growth GYRE Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 13.2% na
Net Income (5yr) na (10.7%) na
EPS (5yr) na 15.5% na
Dividends (5yr) na 0.0% 0%
Cash Flow (5yr) na (15.7%) na
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates na na na
Current EPS ($0.073) ($0.275) ($0.200)
Month Ago EPS na na na
# Rev Up 0 0 0
# Rev Down 0 3 2
Three Months Ago EPS na na na
Year/Year Chg 82.5% (1,350%) 8,764%
Financials GYRE Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $110 $39 27%
Net Income (TTM) (Mil) ($25) ($44) 22%
EPS (TTM) ($0.257) ($1.400) 31%
Operating Cash Flow (TTM) (Mil) ($6) ($34) 24%
Net Cash Flow (TTM) (Mil) ($11) $-0 32%
Long-Term Debt (Q1) (Mil) $2 $4 20%
Enterprise Value (Q1) (Mil) $512 $135 35%
Valuation GYRE Industry
Median
Percentile
(All Stocks)
P/B 4.30 1.97 78%
P/E na 17.6 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 0.8 na
Ratios GYRE Industry
Median
Percentile
(All Stocks)
Gross Margin 93.5% 67.9% 95%
Net Margin (22.7%) (50.8%) 16%
ROA (13.9%) (47.5%) 22%
ROE (23.8%) (51.9%) 22%
Liabilities to Assets 17.5% 29.7% 11%
F-Score 1 3 na

Gyre Therapeutics, Inc. did not pass any screens on 11/18/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors